<?xml version="1.0" encoding="UTF-8"?>
<p>Other drugs are under investigation. According to the World Health Organization's Coronavirus Roadmap, remdesivir is considered a “first priority” drug due to its broad antiviral spectrum, with the in vitro and in vivo effectiveness against coronaviruses and the extensive clinical safety already documented.
 <xref rid="eahr500060-bib-0013" ref-type="ref">
  <sup>13</sup>
 </xref> However, many current trials registered to study remdesivir in participants with moderate to severe infection also exclude pregnant women. A second priority is among antiretrovirals (HIV protease inhibitors). The combination of lopinavir and ritonavir has been widely used in HIV‐positive pregnant women. Nevertheless, pregnant women are still excluded from some of the trials involving this antiviral regimen for Covid‐19 infection.
 <xref rid="eahr500060-bib-0014" ref-type="ref">
  <sup>14</sup>
 </xref> The emerging picture prompts important questions about the reasons to exclude pregnant women from or delay their involvement in clinical trials during this pandemic.
</p>
